C1qTNF3/CORS26/CTRP3 Antibody (860115) [Alexa Fluor™ Plus 680]

• Clone: 860115
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 680

C1qTNF3/CORS26/CTRP3 Antibody (860115) [Alexa Fluor™ Plus 680] Summary

• Specificity: Detects human CTRP3/C1qTNF3/CORS26 in direct ELISAs.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for C1qTNF3/CORS26/CTRP3 Antibody (860115) [Alexa Fluor™ Plus 680]

• C1ATNF3
• C1q and tumor necrosis factor related protein 3
• C1qTNF3
• Cartducin
• cartonectin
• collagenous repeat-containing sequence of 26-kDa
• complement C1q tumor necrosis factor-related protein 3
• complement-c1q tumor necrosis factor-related protein 3
• Corcs
• Cors
• CORS26
• Cors-26
• CTRP3
• CTRP32310005P21Rik
• FLJ37576
• Secretory protein CORS26

Background

CTRP3 (Complement C1q TNF-related Protein 3/C1qTNF3) also known as CORS-26 (Collagenous Repeat-containing Sequence of 26 kDa protein), Cartonectin and Cartducin, is a 30-32 kDa, secreted member of the C1q and TNF-related (CTRP) superfamily of molecules (1). The mature protein is 224 aa in length. It contains an N-terminal collagen-like domain followed by a C-terminal globular region. Human CTRP3 shares 99% aa sequence identity with the mouse CTRP3 (2). Like other CTRP members, CTRP3 has a trimeric structure and can assemble into hexameric or higher order molecular forms (3). It is expressed by a variety of cells, including adipocytes, cartilage, fibroblasts, monocytes and proliferating chondrocytes (4). The inflammatory effects of LPS, TLR-4 and fatty acids have been shown to be inhibited by CTRP3 in adipocytes and monocytes (5). In mouse models, CTRP3 has been shown to lower glucose levels and decrease gluconeogenic gene expression (6). Inhibition of 3T3-L1 pre-adipocyte differentiation to adipocytes is associated with CTRP3 treatment, demonstrating potential anti-obesity effects (7). Treatment with CTRP3 results in the proliferation of skeletal muscle C2C12 cells and inhibition of C2C12 myotube differentiation, mediated by the ERK pathway (8). Due to the variety of functions in metabolism and inflammation, CTRP3 is a potential new target of type 2 diabetes treatment.

1. Wong, G.W. et al. (2004) Proc. Natl. Acad. Sci. U.S.A. 101:10302.
2. Schaffler A. et al. (2003). Biochim Biophys Acta.1630:123.
3. Suzuki S. et al. (2007) FEBS Lett. 581: 809.
4. Weigert J. et al. (2005) FEBS Lett. 579: 5565.
5. Kopp, A. et al. (2010) Endocrinology. 151:5267.
6. Peterson J. M. et al. (2010) J Biol Chem. 285:39691.
7. Nishimoto, H. et al. (2017) Cell Bio Int. 41:197.
8. Otani M. et al. (2015) Mol Cell Biochem. 409:271.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.